10-K/A: Accuray Restates FY25 Financials, Cites RPO Disclosure Errors

Accuray Incorporated has restated its fiscal year 2025 financial statements and prior interim periods due to errors in remaining performance obligations disclosure and identified material weaknesses in internal controls.

Summary

• Accuray Incorporated filed a Form 10-K/A to restate its consolidated financial statements for the fiscal year ended June 30, 2025, and interim periods ended September 30, 2024, December 31, 2024, and March 31, 2025.
• The restatement was necessary due to errors in the disclosure of remaining performance obligations (RPO) in Note 2, Revenue, as the company incorrectly included executed open system orders, upgrade sales orders, and customer credits within RPO balances.
• The correction significantly reduced the reported RPO balances: from $818.2 million to $60.9 million at June 30, 2025; from $886.1 million to $56.9 million at March 31, 2025; from $886.7 million to $55.4 million at December 31, 2024; and from $902.4 million to $58.8 million at September 30, 2024.
• The identified errors did not impact the audited or unaudited Balance Sheets, Statements of Operations and Comprehensive Loss, Statements of Stockholders Equity, or Statements of Cash Flows.
• Management reevaluated its internal control over financial reporting (ICFR) and disclosure controls and procedures (DCP), concluding they were not effective as of June 30, 2025, and the end of each affected period, respectively.
• Two material weaknesses were identified: 1) deficiencies in the review of footnote schedules supporting financial statement disclosures, and 2) inadequate controls to appropriately analyze all relevant information for complete and accurate GAAP presentation and disclosure, stemming from an incorrect assessment during the initial adoption of ASC 606.
• The Audit Committee determined that the previously issued financial statements for the affected periods should no longer be relied upon.
• Accuray completed a debt refinancing on June 6, 2025, entering into a new five-year senior secured credit agreement for a $150 million Term Loan Facility, a $20 million Delayed Draw Facility, and a $20 million Revolving Credit Facility, all maturing June 6, 2030.
• Proceeds from the Term Loan Facility were used to refinance existing senior secured indebtedness ($58.0 million Prior Term Loan, $17.0 million Prior Revolving Credit) and fund a $68.5 million cash payment for an exchange of Convertible Notes.
• The company exchanged approximately $82.0 million aggregate principal amount of 3.75% Convertible Senior Notes due June 1, 2026, for 8,881,579 shares of common stock and $68.5 million in cash, leaving $18.0 million principal amount of Convertible Notes outstanding.
• In connection with the new financing, Accuray issued detachable warrants to lenders: 17,180,710 Premium Warrants (exercise price $1.68, exercisable from December 7, 2025) and 6,247,531 Penny Warrants (exercise price $0.01, immediately exercisable).

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a significantly negative development due to the restatement of financial disclosures and the identification of material weaknesses in internal controls, leading to an adverse auditor opinion on ICFR, which undermines confidence in financial reporting reliability.

Positives

• Net loss significantly reduced from $(15,545) thousand in fiscal year 2024 to $(1,591) thousand in fiscal year 2025.
• Income from operations increased from $504 thousand in fiscal year 2024 to $7,839 thousand in fiscal year 2025.
• Gross profit increased from $142,921 thousand in fiscal year 2024 to $146,967 thousand in fiscal year 2025.
• Total stockholders' equity increased from $45,084 thousand in fiscal year 2024 to $81,169 thousand in fiscal year 2025.
• The joint venture's net income increased from $3,750 thousand (12 months ended March 31, 2024) to $9,617 thousand (12 months ended March 31, 2025).
• The joint venture declared a $2.5 million dividend to the Company in June 2025, which was paid in July 2025.
• Two previously identified material weaknesses (SAP S/4HANA ERP system controls for manual journal entries and inventory existence) were remediated by December 31, 2024, and March 31, 2025, respectively.
• Successful refinancing of existing senior secured indebtedness and partial exchange of Convertible Notes, extending debt maturity to June 6, 2030.

Negatives

• Restatement of previously issued financial statements for fiscal year 2025 and prior interim periods due to RPO disclosure errors.
• Identification of two new material weaknesses in internal control over financial reporting as of June 30, 2025.
• Management and the independent auditor concluded that internal control over financial reporting and disclosure controls and procedures were not effective as of June 30, 2025.
• Accumulated deficit increased from $(517,681) thousand in fiscal year 2024 to $(519,272) thousand in fiscal year 2025.
• Ongoing adverse impact expected on gross margins and net income (loss) from increased material costs and freight/logistics expenses through at least calendar year 2025, and potentially longer.
• Expected impact on cash from operations through at least calendar year 2025 due to inflation and supply chain challenges.
• Reduced budgets and longer customer installation timelines in the United States have negatively impacted net revenue since fiscal year 2024 and are expected to continue through fiscal year 2026.
• The company has substantial indebtedness, including a $150 million Term Loan Facility and $18.0 million in Convertible Notes outstanding.
• In the past, the company has not been in compliance with certain financial covenants relating to its indebtedness and has been required to obtain waivers.

Risks

• Global economic environment, including tariffs, inflation, recession, or currency fluctuations, could adversely affect business, financial condition, and results of operations.
• Inability to achieve widespread market acceptance for CyberKnife or TomoTherapy platforms could hinder revenue generation.
• Failure to maintain or increase gross margins on product sales and services could prevent profitability.
• Substantial indebtedness and potential future debt could adversely affect financial condition and results; past non-compliance with financial covenants required waivers.
• Enhanced international tariffs, trade barriers, or a global trade war could decrease product sales in China and increase costs.
• Operating results, cash flows, quarterly orders, revenues, and margins are subject to fluctuation and may be unpredictable.
• Intense competition and rapid technological change in the medical device industry could render products obsolete.
• Risks from international operations, including economic/political instability, regulatory changes, trade policies, and foreign currency fluctuations.
• Manufacturing problems or failure to meet manufacturing standards could lead to temporary cessation of operations, delays, and lost revenue.
• Inability to develop new products or enhance existing ones to meet customer needs could hinder customer attraction/retention.
• Failure to effectively manage growth could significantly harm the business.
• Potential for product liability claims, product recalls, other field actions, and warranty claims, which could be expensive and divert management attention.
• Reliance on single-source suppliers for critical components could harm ability to meet demand timely and cost-effectively.
• Dependence on key employees; failure to attract and retain expertise could adversely affect business growth.
• Disruption of critical information technology systems, infrastructure, data, or cyberattacks could harm business and financial condition.
• Failure to comply with legal/regulatory requirements related to privacy, cybersecurity, and data protection could result in proceedings, actions, or penalties.
• Insufficient third-party payor coverage and reimbursement for product use, or reduction in insured patients, could adversely affect demand and revenue.
• Safety and efficacy of products for certain uses not yet supported by long-term clinical data.
• Failures or disruptions at logistics providers could adversely impact business.
• Third parties may claim infringement of intellectual property or violation of license agreements, leading to expenses, liabilities, or sales disruptions.
• Difficulty and cost in protecting intellectual property and proprietary technologies.
• Identified material weaknesses in internal controls as of June 30, 2025; failure to remediate could impact timely and accurate financial reporting.
• Modifications, upgrades, new indications, and future products may require new FDA clearances/approvals and similar international licensing.
• Violation of federal, state, and foreign laws and regulations applicable to operations could result in substantial penalties.
• Failure to obtain and maintain necessary regulatory approvals in specific countries could prevent product marketing and sales.
• Volatility in common stock price.
• Future issuances of common stock could dilute ownership interests.
• Exercise of outstanding warrants could increase shares eligible for resale and result in dilution.
• Conditional conversion features of 2026 Notes, if triggered, may adversely affect financial condition and operating results.
• Provisions in debt indentures, certificate of incorporation, and bylaws could discourage or prevent a takeover.
• Liquidity could be adversely impacted by adverse conditions in financial markets.
• Operations vulnerable to interruption or loss due to climate change, natural disasters, pandemics, terrorist acts, and other events beyond control.
• Changes in interpretation or application of generally accepted accounting principles may adversely affect operating results.
• No dividends paid in the past, and none expected in the foreseeable future.
• Inability to fully utilize certain tax loss carryforwards.
• Subject to tax laws of various foreign jurisdictions and the U.S., which are subject to unanticipated changes and interpretation.

Future Outlook

Accuray expects gross margins and net income (loss) to continue to be adversely affected by increased material costs and freight and logistics expenses through at least calendar year 2025, and potentially longer. Inflation and ongoing supply chain challenges are also anticipated to impact cash from operations through at least calendar year 2025. Additionally, reduced budgets and longer customer installation timelines in the United States are projected to negatively impact net revenue through fiscal year 2026.

Management Comments

• Management is actively engaged in the planning for, and implementation of, remediation efforts to address the material weakness identified above, but remediation efforts can be time consuming and costly.
• Management has concluded that the Company's consolidated financial statements included in this Annual Report on Form 10-K/A fairly present, in all material respects, our financial position, results of operations and cash flows for the periods presented with accounting principles generally accepted in the United States of America.
• Based on the balance of the Company's cash and cash equivalents, available debt facilities, current business plan and revenue prospects, the Company believes that it will have sufficient cash resources and anticipated cash flows to fund its operations for at least the next 12 months.

Industry Context

StockSavvy.ai notes that the medical device industry, particularly non-invasive cancer treatment, is highly competitive and subject to rapid technological change. Accuray's reliance on its CyberKnife and TomoTherapy platforms places it in direct competition with larger, well-capitalized companies like Varian Medical Systems (a Siemens Healthineers company) and Elekta AB, which hold significant market share. The industry also faces macroeconomic headwinds such as inflation, supply chain disruptions, and geopolitical instability, which Accuray explicitly states are impacting its gross margins, net income, and cash from operations. The ongoing consolidation in the healthcare industry and pressures on hospital capital expenditure budgets further intensify pricing competition and can delay product adoption.

Comparison to Industry Standards

• StockSavvy.ai observes that Accuray's reported net loss of $(1.6) million for fiscal year 2025, while an improvement from $(15.5) million in fiscal year 2024, still indicates a struggle for consistent profitability compared to industry leaders like Varian Medical Systems, which typically reports substantial net income.
• The increase in gross profit to $147.0 million in fiscal year 2025 from $142.9 million in fiscal year 2024 suggests some operational improvements, but the company's explicit warning about continued adverse impacts on gross margins from material costs and logistics through at least calendar year 2025 indicates ongoing challenges that may lag behind more resilient competitors.
• The identification of material weaknesses in internal controls and an adverse auditor opinion on ICFR is a significant deviation from best practices among established medical device companies, which typically maintain effective internal controls to ensure reliable financial reporting. This contrasts sharply with the robust control environments expected from peers.
• The successful refinancing of debt and partial exchange of convertible notes, while positive for liquidity management, also highlights the company's ongoing need to manage substantial indebtedness, a common challenge for growth-oriented medical technology firms but one that can be more acutely felt by companies with fluctuating profitability.
• Accuray's joint venture in China, CNNC Accuray, shows strong growth in net income ($9.6 million in 12 months ended March 31, 2025, up from $3.8 million), which is a positive indicator for its strategic expansion in a key international market, potentially outperforming some competitors' direct market entry strategies in terms of local market penetration.

Management Changes

Corporate Governance

Legal Proceedings

• Involved in various lawsuits, claims, investigations, and inquiries in the ordinary course of business (e.g., intellectual property, product liability, employment, class action, whistleblower, and other litigation claims, and governmental and other regulatory investigations and proceedings).
• Management believes there are no probable and reasonably estimable material losses related to any current legal proceedings and claims as of June 30, 2025.
• Under audit by the Indian tax authorities for the fiscal year 2021, with no material impact expected on consolidated financial statements.

Related Party Transactions

• Accounts receivable from CNNC Accuray (Tianjin) Medical Technology Co. Ltd. (JV), an equity method investment, of $28,452 thousand at June 30, 2025, and $25,339 thousand at June 30, 2024.
• Sales of services to the JV of $18,521 thousand during fiscal year 2025 and $15,039 thousand during fiscal year 2024.
• Other receivable from the JV of $377 thousand at June 30, 2025, and $743 thousand at June 30, 2024.
• Cost of revenue from sales to the JV of $74,421 thousand during fiscal year 2025 and $59,853 thousand during fiscal year 2024.
• Charge backs to the JV related to research and development of $1,482 thousand during fiscal year 2025 and $942 thousand during fiscal year 2024.
• The JV declared a $2.5 million dividend to the Company in June 2025 (paid July 2025) and $2.5 million in June 2024 (paid fiscal year 2025).

Stakeholder Impact

• Shareholders: Potential dilution from warrant exercises and future equity raises; reduced confidence due to restatement and material weaknesses in internal controls; stock price volatility risk.
• Employees: Share-based compensation (stock options, RSUs, PSUs, ESPP) is a significant part of compensation; potential impact on morale and retention due to financial reporting issues and past reductions in force.
• Customers: Potential delays in product delivery and installation due to macroeconomic factors, supply chain issues, and longer installation timelines; reliance on third-party payor reimbursement.
• Suppliers: Risks due to reliance on single-source suppliers for critical components; potential for increased costs and supply chain disruptions.
• Creditors: Substantial indebtedness under new credit facilities and remaining convertible notes; compliance with financial covenants is critical to avoid default.
• Regulatory Authorities: Increased scrutiny and potential enforcement actions due to material weaknesses and restatement; ongoing compliance with FDA, international medical device regulations, privacy laws (HIPAA, GDPR, PIPL), anti-corruption laws (FCPA), and transparency laws (Sunshine Act).

Next Steps

• Management is actively engaged in planning and implementing remediation efforts for the identified material weaknesses related to footnote disclosure review and GAAP analysis.
• The company will continue to evaluate and modify the remediation plan as appropriate.
• The company will consider the material weaknesses remediated when enhanced controls have operated for a sufficient period and are deemed effective.
• The company plans to adopt ASU 2024-03 (additional expense disclosures) on July 1, 2027.
• The company plans to adopt ASU 2023-09 (income tax disclosures) on July 1, 2025, with retrospective application.
• The company will continue to monitor its recorded goodwill for indicators of impairment every fiscal quarter.
• The company expects total contributions to the defined benefit pension plan for fiscal year 2026 will be approximately $1.5 million.
• The company is evaluating the full impact of the OBBB Act (new federal tax legislation enacted July 4, 2025) on future periods.
• The company will be able to access the Delayed Draw Down Facility from the date financial reports are delivered for the fiscal quarter ending December 31, 2025, through June 6, 2026, if certain total leverage ratio conditions are met.

Key Dates

Recommendation

The restatement of financial disclosures and the identification of material weaknesses in internal controls, leading to an adverse auditor opinion on ICFR, are significant concerns that typically warrant a cautious stance. While the company shows some positive operational improvements like reduced net loss and increased gross profit, and has remediated some prior weaknesses, the current control deficiencies create uncertainty regarding the reliability of future financial reporting. The debt refinancing provides some stability, but ongoing macroeconomic headwinds and competitive pressures suggest a "hold" recommendation until the remediation efforts for the material weaknesses are fully effective and sustained improvements in financial controls and operational consistency are demonstrated.

Keywords

SEC filing, 10-K/A, restatement, financial statements, remaining performance obligations, RPO, material weaknesses, internal control over financial reporting, disclosure controls and procedures, ASC 606, revenue recognition, Accuray Incorporated, ARAY, medical devices, radiation therapy, CyberKnife, TomoTherapy, debt refinancing, convertible notes, warrants, corporate governance, risk management, financial reporting, auditor opinion, Grant Thornton LLP, joint venture, China, healthcare industry, macroeconomic factors, supply chain, inflation, regulatory compliance, intellectual property, stock volatility